Table 4 Univariate and multivariate analyses of overall survival in patients with hormone receptor-positive/HER2-negative primary breast cancer
Univariate | Multivariate | |||||||
|---|---|---|---|---|---|---|---|---|
Total | Hazard | (95% CI) | P-value | Hazard | (95%CI) | P-value | ||
(n=142) | ratio | ratio | ||||||
Ki67-p53 | Low Ki67 LI and Negative p53 | 88 | 1 | 1 | ||||
High Ki67 LI and/or Positive p53 | 54 | 8.8 | 1.9-40.4 | 0.0049 | 7.9 | 1.7-36.7 | 0.0081 | |
FOXA1 | Low | 20 | 1 | |||||
High | 119 | 0.49 | 0.06-3.9 | 0.50 | ||||
GATA3 | Negative | 30 | 1 | |||||
Positive | 112 | 1.1 | 0.31-4.3 | 0.84 | ||||
Basal phenotype marker | Negative | 9 | 1 | |||||
(CK5/6, CK14, EGFR) | Positive | 133 | 1.2 | 0.15-9.3 | 0.86 | |||
P-cadherin | Low | 90 | 1 | |||||
High | 52 | 1.8 | 0.57-5.5 | 0.32 | ||||
Tumor size | <5.0cm | 17 | 1 | |||||
≧5.0cm | 122 | 3.4 | 0.90-12.8 | 0.071 | ||||
Lymph-node metastasis | (−) | 80 | 1 | |||||
(+) | 59 | 3.9 | 1.02-14.7 | 0.045 | ||||
Nuclear grade | 1, 2 | 111 | 1 | |||||
3 | 31 | 3.8 | 1.2-11.9 | 0.0020 | ||||
Chemotherapy | No | 93 | 1 | |||||
Yes | 49 | 2.0 | 0.65-6.3 | 0.22 | ||||